As of Aug 22
| +1.22 / +3.41%|
The 14 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 64.00, with a high estimate of 102.00 and a low estimate of 33.00. The median estimate represents a +73.21% increase from the last price of 36.95.
The current consensus among 15 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.